



# ADVIK LABORATORIES LIMITED

ALL/BSE/ASE/OUT-BM/Q2/1819/535

Dated: 13th November, 2019

To,  
The Manager (Listing)  
BSE Limited  
1<sup>st</sup> Floor, P.J. Towers  
Dalal Street, Mumbai – 400001

Sub: Outcome of the Board Meeting and Submission of Unaudited Financial Results for the quarter and half year ended 30th September, 2019 as required u/r 33 of the SEBI (LODR) Regulations, 2015.

Ref: BSE Scrip Code 531686; ASE Scrip Code- 01638 (ADVIK LABO)

Dear Sir,

This is to inform you that in pursuance to Regulation 33 of SEBI (LODR) Regulations, 2015, the Board of Directors of the Company in its meeting held on Wednesday, 13th November, 2019 at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi – 110001 and concluded just now has, inter-alia, transacted the following businesses:

1. Considered and Approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2019.
2. Considered and taken on records Limited Review Report submitted by the Statutory Auditors of the company for the Unaudited Financial Results for the quarter and half year ended 30th September, 2019.
3. The Board also considered and took note of the request letter dated 30.09.19 sent to Indian Overseas Bank (IOB) wherein the company has requested IOB to allow it the time upto 31<sup>st</sup> December, 2019 to settle its outstanding debts of IOB, as per the terms of One Time Settlement (OTS) entered into by the company with the IOB, which the company was supposed to settle by 30<sup>th</sup> September, 2019. The request letter of the company is under consideration at the end of IOB. The Board also considered and took note of the efforts being made by the management of the company for arranging the necessary funds to clear the outstanding debts of IOB.

Further pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, a copy of the aforesaid Financial Results for the quarter and half year ended 30th September, 2019 alongwith Limited Review Report of the Statutory Auditors thereon are enclosed herewith for your kind perusal.

Kindly take the aforesaid information in your records.

Thanking you.

Yours Truly,  
For Advik Laboratories Limited

  
Pooja Chuni  
Company Secretary  
Encl: As stated above



CC:

The Manager (Listing)  
Ahmedabad Stock Exchange Limited  
1st Floor, Kamdhenu Complex  
Opp. Sahajanand College,  
Panjara Pole, Ambawadi, Ahmedabad – 380015

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi - 110001

Phones : 011-42424884, 43571040-45, Fax : 011-43571047

Regd. Office & Factory : 138, ROZ-Ka Meo, Industrial Area, Sohna - 122103 (Distt. Mewat), Haryana

Phones : 0124-2362471 E-mail : mail@advikindia.com Website : www.advikindia.com

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2019**

CIN : L74899HR1994PLC038300

Sr No	Particulars	(Rs in Lacs except EPS)					
		For the Quarter ended			For the half year ended		Year Ended
		30-Sep-19 (Unaudited)	30-Jun-19 (Unaudited)	30-Sep-18 (Unaudited)	30-Sep-19 (Unaudited)	30-Sep-18 (Unaudited)	31-Mar-19 (Audited)
<b>1</b>	<b>Income from Operation</b>						
	(a) Net Sales/Revenue from Operations	-	-	82.44	-	82.44	82.44
	(b) Other Operating Income	-	0.44	-	0.44	-	0.37
	(c) Other Income	0.02	0.20	0.37	0.22	0.37	1.70
	<b>Total Income</b>	<b>0.02</b>	<b>0.64</b>	<b>82.81</b>	<b>0.66</b>	<b>82.81</b>	<b>84.51</b>
<b>2</b>	<b>Expenses</b>						
	a) Cost of Materials consumed	-	-	-	-	0.28	0.34
	b) Purchase of Stock-in-trade	-	-	-	-	82.16	82.16
	c) Changes in Inventory of Finished goods, Work-in-progress and Stock-in-trade	-	-	82.16	-	-	-
	d) Employee Benefits Expenses	11.28	10.61	12.61	21.89	24.88	48.57
	e) Finance Costs	0.06	0.01	0.04	0.07	0.15	0.31
	f) Depreciation and Amortisation expense	14.65	14.64	14.70	29.29	29.40	58.79
	g) Other expenses	3.98	5.17	5.21	9.15	10.98	23.63
	<b>Total Expenses</b>	<b>29.97</b>	<b>30.43</b>	<b>114.72</b>	<b>60.40</b>	<b>147.85</b>	<b>213.80</b>
<b>3</b>	<b>Profit/(Loss) before Exceptional items and tax (1-2)</b>	<b>(29.95)</b>	<b>(29.79)</b>	<b>(31.91)</b>	<b>(59.74)</b>	<b>(65.04)</b>	<b>(129.29)</b>
<b>4</b>	<b>Exceptional Items</b>	-	-	-	-	-	-
<b>5</b>	<b>Profit/(Loss) before tax (3 + 4)</b>	<b>(29.95)</b>	<b>(29.79)</b>	<b>(31.91)</b>	<b>(59.74)</b>	<b>(65.04)</b>	<b>(129.29)</b>
<b>6</b>	<b>Tax Expense</b>						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	(2.26)	(2.27)	(1.33)	(4.53)	(2.67)	(4.69)
	<b>Total Tax Expenses</b>	<b>(2.26)</b>	<b>(2.27)</b>	<b>(1.33)</b>	<b>(4.53)</b>	<b>(2.67)</b>	<b>(4.69)</b>
<b>7</b>	<b>Profit/(Loss) for the period ( 5-6)</b>	<b>(27.69)</b>	<b>(27.52)</b>	<b>(30.58)</b>	<b>(55.21)</b>	<b>(62.37)</b>	<b>(124.60)</b>
<b>8</b>	<b>Other Comprehensive Income (net of tax)</b>	<b>0.33</b>	<b>0.33</b>	<b>0.43</b>	<b>0.66</b>	<b>0.86</b>	<b>1.32</b>
<b>9</b>	<b>Total Comprehensive Income for the period ( 7+8)</b>	<b>(27.36)</b>	<b>(27.19)</b>	<b>(30.15)</b>	<b>(54.55)</b>	<b>(61.51)</b>	<b>(123.28)</b>
<b>10</b>	<b>Paid-up equity share capital ( face value of Rs 10/- per</b>	<b>1,911.14</b>	<b>1,911.14</b>	<b>1,911.14</b>	<b>1,911.14</b>	<b>1,911.14</b>	<b>1,911.14</b>
<b>11</b>	<b>Earning per share (EPS) of Rs 10/- each (not annualized)</b>						
	(1) Basic	(0.14)	(0.14)	(0.16)	(0.29)	(0.33)	(0.65)
	(2) Diluted	(0.14)	(0.14)	(0.16)	(0.29)	(0.33)	(0.65)

**NOTES:-**

1	The above Financial Results for the quarter & half year ended September 30, 2019 has been reviewed by the Audit Committee and thereafter approved by the Board of Directors & taken on record at its meeting held on November 13, 2019. A Limited review of the same has been carried out by the Statutory Auditors.
2	The Company operates in a single segment viz pharmaceuticals formulations and the results pertain to a single segment in accordance with IND AS 108-Operating Segment.
3	The Company has adopted Indian Accounting Standards ("Ind AS") notified by the Ministry of Corporate Affairs. This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting practices and policies to the extent applicable.
4	The format for un-audited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016. IND AS and Schedule III (Division II) to the Companies Act, 2013 applicable to the companies that are required to comply with IND AS.
5	In the absence of any orders, there is a decline in the operating activities of the company. The company is making necessary efforts to find the prospective buyers and get the new orders. Management of the company believes that the new deals would be finalized soon.



6	<p><b>Auditor's Observation:-</b></p> <p>1. Due to default in payments of bank loans, the company's accounts have been classified as Non-Performing Assets (NPA) by the bank. Indian Overseas Bank has not charged interest on Cash credit &amp; Term Loan Limits. During the period under review no provision has been made for such interest in the books of account of the company and to that extent bank's loan liability and total loss is understated by Rs. 636.72 lacs plus penal charges that the bank may charge.</p> <p>2. The company had recorded the cost of the investment at the face value of the equity shares issued and had not determined the fair value as required by IND AS. In the absence of the fair value of the securities acquired we are unable to express an opinion on the value of the investment recorded.</p>
7	<p><b>Our explanation to Auditor's Observation:-</b></p> <p>1. The Company's accounts had become Non Performing Assets (NPA) with Indian Overseas Bank and due to this reason, Indian Overseas Bank has stopped charging interest from the company on its outstanding debts. In view of the above, the company has not charged to statement of Profit &amp; Loss account Interest expenses of Rs. 42.71 Lacs and related penal interest &amp; other charges, if any, for the reported period, in respect of delay of repayments of borrowings from the bank. Further liability for interest exepnses of Rs.594.02 lacs till 30/06/2019 has not been accounted for. The company has made necessary efforts to reach One Time Settlement with Indian Overseas Bank &amp; had sent the One Time Settlement proposal with Indian Overseas Bank which has been approved by the Bank. As per the terms of the aforesaid One Time Settlement, the company was supposed to clear its outstanding debt by 30th September 2019. However, due to paucity of funds, the company was unable to clear the debts of IOB. At present the company is trying to arrange the necessary funds to settle its outstanding debts of IOB and further our company has made a request to IOB vide its letter dated 30.09.19 to allow a time upto 31st December, 2019 in order to enable it to settle its outstandings as per the terms of aforesaid OTS. The same is under consideration at the end of IOB.</p> <p>2. The company has misplaced/lost the share certificates of the Investment made by it in unquoted equity shares of other companies during the shifting of its records. Hence these share certificates are not physically held by the company. The Company has sent various request letters to the companies in which it has made investments for issue of duplicate share certificates. However, till date the company has not received any reply from these companies. In order to ensure the compliance of IND AS in true letter and spirits, the company is also trying to ascertain the fair market value of its investments.</p>
8	<p>Previous year/period figures have been regrouped/arranged, wherever necessary to make them comparable with the current period figure.</p>

**For and on behalf of Board of Directors of Advik Laboratories Ltd.**

*(Signature)*

(Peeyush Kumar Aggarwal)

Chairman

DIN : 00090423



Place: New Delhi

Date : 13th November, 2019



Statement of Assets & Liabilities as on September 30, 2019

(Rs. In lacs)

Particulars		As at 30.09.19 (Unaudited)	As at 31.03.19 (Audited)
<b>A.</b>	<b>ASSETS</b>		
1	<b>Non Current Assets</b>		
	Property Plant & Equipment	558.99	588.27
	Capital Work in progress	514.62	542.67
	Other Intangible Assets	-	-
	<b>Non Current Assets</b>	<b>1,073.61</b>	<b>1,130.94</b>
	<b>Non Current Financial Assets</b>		
	Investments	92.30	92.30
	Other Non Current Assets	0.48	0.48
	<b>Total-Non current assets</b>	<b>1,166.39</b>	<b>1,223.72</b>
2	<b>Current Assets</b>		
	Inventories	57.11	57.11
	<b>Current Financial Assets</b>		
	Trade receivables	258.54	261.34
	Cash & cash equivalents	1.65	1.57
	Loans and advances	211.79	211.51
	Other current assets	0.21	0.46
	<b>Total Current Assets</b>	<b>529.30</b>	<b>531.99</b>
	<b>TOTAL ASSETS</b>	<b>1,695.69</b>	<b>1,755.71</b>
<b>B.</b>	<b>EQUITY &amp; LIABILITIES</b>		
1	<b>EQUITY</b>		
	Equity Share Capital	1,911.14	1,911.14
	Other Equity	(1,012.97)	(958.42)
	<b>Total Equity</b>	<b>898.17</b>	<b>952.72</b>
2	<b>LIABILITIES</b>		
	<b>Non-Current Liabilities</b>		
	Non-Current Financial Liabilities	-	-
	Other Financial Liabilities	-	-
	Long Term Provisions	17.72	11.57
	Deferred tax liabilities	63.98	68.51
	<b>Total-Non Current Liabilities</b>	<b>81.70</b>	<b>80.08</b>
	<b>Current Liabilities</b>		
	<b>Current Financial Liabilities</b>		
	Borrowings	252.66	250.53
	Trade payables	10.99	16.30
	Other current financial liabilities	452.17	456.08
	<b>Total Current Financial Liabilities</b>	<b>715.82</b>	<b>722.91</b>
	<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>1,695.69</b>	<b>1,755.71</b>

For and on behalf of Board of Directors of Advik Laboratories Ltd.

(Peeyush Kumar Aggarwal)  
Chairman  
DIN : 00090423



Place: New Delhi  
Date : 13th November, 2019

**Statement of Cash Flows as on September 30, 2019**

(Rs. In lacs)

	Particulars	As at 30.09.19 (Unaudited)	As at 30.09.18 (Unaudited)
<b>A.</b>	<b>Cash Flow from operating activities</b>		
	Net profit before tax and extraordinary items	(59.74)	(65.04)
	Add: Adjustment for Depreciation	29.29	29.40
	Provision for Gratuity	0.95	1.07
	Provision for Leave Encashment	0.27	0.32
	Finance Cost	0.07	0.15
	<b>Operating profit before working capital changes</b>	<b>(29.16)</b>	<b>(34.10)</b>
	<b>Adjustment for:</b>		
	Increase / (Decrease) in Trade Payables	(5.31)	2.03
	Increase / (Decrease) in other Current Liabilities	1.67	2.02
	(Increase) / Decrease in Trade Receivables	2.80	56.36
	(Increase) / Decrease in Loans & Advances	(0.28)	(1.28)
	(Increase) / Decrease in Other Current Assets	0.25	(1.31)
	(Increase) / Decrease in Inventories	-	0.28
	<b>Net Cash generated/(used in) from operating activities</b>	<b>(30.03)</b>	<b>24.00</b>
<b>B.</b>	<b>Cash flow from investing activities</b>		
	Increase/(Decrease) in Capital work in progress	28.05	15.12
	<b>Net cash outflow from investing activities</b>	<b>28.05</b>	<b>15.12</b>
<b>C.</b>	<b>Cash Flow from financing activities</b>		
	Proceeds from/ (Repayment of) current borrowings	2.13	(40.00)
	Finance Cost	(0.07)	(0.15)
	<b>Net cash used in financial Activities</b>	<b>2.06</b>	<b>(40.15)</b>
	<b>Net Increase/ (Decrease) in cash &amp; cash equivalents (A+B+C)</b>	<b>0.08</b>	<b>(1.03)</b>
	Cash & Cash Equivalents (Opening balance)	1.57	1.56
	<b>Cash &amp; Cash Equivalents (Closing balance)</b>	<b>1.65</b>	<b>0.53</b>

For and on behalf of Board of Directors of  
Advik Laboratories Limited

(Peeyush Kumar Aggarwal)

Chairman

DIN :0090423



Place: New Delhi

Date 13th November, 2019



# RMA & ASSOCIATES LLP

Chartered Accountants  
LLPIN: AAI-9419 (ISO 9001:2015)

Address : A-13, Ground Floor, Lajpat  
Nagar-III, New Delhi - 24

Phone : 011-49097836

Email : ca.jamit@gmail.com

Website : www.rma-ca.com

**Independent Auditors Review Report on Quarterly Unaudited Standalone Financial Results of the  
company for the quarter and half year ended September, 2019  
(Pursuant to the Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements)  
Regulations, 2015**

**The Board of Directors of  
Advik Laboratories Limited**

We have reviewed the accompanying statement of unaudited Standalone financial results of M/s Advik Laboratories Limited for the quarter & half year ended on 30th September, 2019 being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosures Requirements) Regulations, 2015, read with SEBI circular CIR/CFD/CMD1/44/2019 dated March 29, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Attention is drawn to the following points:

- a) Due to default in payments of bank loans, the company's accounts have been classified as Non-Performing Assets (NPA) by the bank. Indian Overseas Bank has not charged interest on cash credit & Term Loan Limits. During the period under review no provision has been made for such interest in the books of account of the company and to that extent bank's loan liability and total loss is understated by Rs. 636.72 lacs plus penal charges that the bank may charges.

b) The company had recorded the cost of the investment at the face value of the equity shares issued and had not determined the fair value as required by IND AS. In the absence of the fair value of the securities acquired we are unable to express as opinion on the value of the investment recorded.

For M/s. RMA & Associates LLP  
Chartered Accountants  
FRN: 000978N/N500062



A handwritten signature in black ink, appearing to read "Amit Jain".

(Amit Jain)  
Partner

(Membership No. 503109)

UDIN: 19503109AAAABS8284

Place : New Delhi

Date: 13<sup>th</sup> November, 2019